0000000000266373

AUTHOR

Alan Hamilton

showing 5 related works from this author

P254 Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat(R) Improves Outcomes Versus Mono-components In Copd In Two 1-year S…

2014

Introduction Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD); olodaterol (O) is a once-daily long-acting β 2 -agonist that has recently gained approval in several countries. Two Phase III replicate pivotal studies assessed the efficacy and safety of fixed-dose combinations of T and O (T+O) delivered via Respimat ® Soft Mist™ inhaler in patients with GOLD 2–4 COPD. Methods Two 52-week, double-blind, parallel-group studies randomised 5162 patients to O 5 µg, T 2.5 µg, T 5 µg, T+O 2.5/5 µg or T+O 5/5 µg. Primary efficacy end points were trough forced expiratory volume in 1 sec…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationArea under the curveAudiologymedicine.diseaseGastroenterologychemistry.chemical_compoundchemistryInternal medicinemedicineRespiratory systemOnce dailybusinessThorax
researchProduct

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

2015

Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patien…

Pulmonary and Respiratory MedicineSpirometryRespimatRespiratory Medicine and Allergy1Fixed-dose combinationOBSTRUCTIVE PULMONARY-DISEASEchemistry.chemical_compoundMedicine and Health SciencesmedicineCOPDCOPDmedicine.diagnostic_testbusiness.industryInhalerOlodaterolArea under the curveOriginal ArticlesTiotropium bromidemedicine.diseaserespiratory tract diseaseschemistryAnesthesiaTRIALbusinessmedicine.drug
researchProduct

P131 Efficacy of tiotropium and olodaterol combination in patients with COPD on β-blockers: Abstract P131 Table 1

2015

Rationale The efficacy and safety of a new once-daily combination with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2-agonist, was established for the treatment of chronic obstructive pulmonary disease (COPD) in the TONADO studies ([NCT01431274][1]; [NCT01431287][2]). This analysis evaluates the efficacy of the combination in a subpopulation of patients receiving β-blockers in these studies. Methods Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O (2.5/5 μg; 5/5 μg; via Respimat® inhaler) once daily compared to the monocomponents. Key primary end-point data for the combined a…

Pulmonary and Respiratory MedicineTreatment interactionmedicine.medical_specialtyCOPDbusiness.industryInhalerOlodaterolArea under the curveUrologyMuscarinic antagonistmedicine.diseaseSurgerychemistry.chemical_compoundchemistrymedicineIn patientPatient groupbusinessmedicine.drugThorax
researchProduct

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers

2015

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TONADO studies (NCT01431274; NCT01431287). This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving β-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 μg; 5/5 μg; Respimat ® inhaler) QD compared to the monocomponents. Key primary end point data for the combined analysis of the replicate trial…

COPDmedicine.medical_specialtyRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseasechemistry.chemical_compoundchemistryInternal medicinemedicinePhysical therapyClinical endpointIn patientbusinessmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

P256 Safety Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat In Chronic Obstructive Pulmonary Disease In Two 1-year St…

2014

Introduction The fixed-dose combination (FDC) of tiotropium (T), a once-daily long-acting muscarinic antagonist, and olodaterol (O), a once-daily long-acting β 2 -agonist, is currently being evaluated in chronic obstructive pulmonary disease (COPD). Two 52-week, Phase III replicate pivotal studies were conducted to assess the efficacy and safety of FDCs of T and O (T+O) delivered via Respimat® Soft Mist™ inhaler in patients (pts) with GOLD Stage 2–4 COPD. Pooled safety data from the two studies are presented here. Methods These were double-blind, randomised, parallel-group studies with 5 arms: O 5 µg, T 2.5 µg, T 5 µg, T+O 2.5/5 µg, T+O 5/5 µg. Key inclusion criteria were: age ≥40 years, di…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseaseGastroenterologySurgerychemistry.chemical_compoundchemistryInternal medicineMedicinebusinessAdverse effectAsthmamedicine.drugThorax
researchProduct